Charles E. Geyer
University of Pittsburgh · 387 works · 50,191 citations · h-index 76
Top works
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
- A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
- Increasing patient involvement in choosing treatment for early breast cancer
- Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer